Jayesh Desai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9214827/publications.pdf

Version: 2024-02-01

207 papers	19,520 citations	38720 50 h-index	11601 135 g-index
208 all docs	208 docs citations	208 times ranked	22624 citing authors

#	Article	IF	Citations
1	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, The, 2006, 368, 1329-1338.	6.3	2,349
2	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncology, The, 2017, 18, 1182-1191.	5.1	2,058
3	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 2019, 575, 217-223.	13.7	1,375
4	KRAS^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. New England Journal of Medicine, 2020, 383, 1207-1217.	13.9	1,049
5	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 2016, 8, 346ra92.	5.8	1,036
6	Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, The, 2007, 370, 2011-2019.	6.3	973
7	Encorafenib, Binimetinib, and Cetuximab in BRAF V600Eâ€“Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	13.9	918
8	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer, 2011, 117, 4623-4632.	2.0	624
9	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4032-4038.	0.8	583
10	Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Annals of Oncology, 2015, 26, 1715-1722.	0.6	517
11	Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors. Journal of Clinical Oncology, 2006, 24, 2325-2331.	0.8	396
12	Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clinical Cancer Research, 2009, 15, 7642-7651.	3.2	395
13	Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors. Annals of Internal Medicine, 2006, 145, 660.	2.0	356
14	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet, The, 2019, 394, 478-487.	6.3	273
15	SMAD2, SMAD3 and SMAD4 Mutations in Colorectal Cancer. Cancer Research, 2013, 73, 725-735.	0.4	260
16	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600Eâ€“Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology, 2021, 39, 273-284.	0.8	254
17	Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. Clinical Cancer Research, 2013, 19, 657-667.	3.2	250
18	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Annals of Oncology, 2014, 25, 1032-1038.	0.6	226

#	Article	IF	Citations
19	Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2007, 13, 2643-2650.	3.2	202
20	Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF^{V600E} mutation. International Journal of Cancer, 2011, 128, 2075-2084.	2.3	200
21	Phase II Study of Ganitumab, a Fully Human Antiâ€“Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors. Journal of Clinical Oncology, 2012, 30, 1849-1856.	0.8	198
22	KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer. Clinical Cancer Research, 2011, 17, 1122-1130.	3.2	193
23	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600Eâ€“Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. Journal of Clinical Oncology, 2019, 37, 1460-1469.	0.8	188
24	PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.. Journal of Clinical Oncology, 2010, 28, 3534-3534.	0.8	177
25	Gastrointestinal Stromal Tumor: New Nodule-within-a-Mass Pattern of Recurrence after Partial Response to Imatinib Mesylate. Radiology, 2005, 235, 892-898.	3.6	151
26	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. American Journal of Gastroenterology, 2013, 108, 1785-1793.	0.2	120
27	Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/Î²-catenin signalling thresholds for tumourigenesis. Oncogene, 2013, 32, 4675-4682.	2.6	117
28	Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2007, 13, 5398-5405.	3.2	116
29	Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. Journal of Clinical Oncology, 2016, 34, 3502-3502.	0.8	114
30	Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Annals of Oncology, 2019, 30, 1134-1142.	0.6	113
31	PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer. Clinical Cancer Research, 2013, 19, 3285-3296.	3.2	107
32	Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis. Clinical Cancer Research, 2011, 17, 416-426.	3.2	106
33	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2â€“Positive Metastatic Breast Cancer. Cancer Discovery, 2019, 9, 354-369.	7.7	104
34	Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas. Clinical Cancer Research, 2004, 10, 5732-5740.	3.2	100
35	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	2.0	96
36	Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clinical Endocrinology, 2008, 69, 669-672.	1.2	95

#	Article	IF	Citations
37	Nivolumab Â± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.. Journal of Clinical Oncology, 2016, 34, 3501-3501.	0.8	90
38	DNA Copy-Number Alterations Underlie Gene Expression Differences between Microsatellite Stable and Unstable Colorectal Cancers. Clinical Cancer Research, 2008, 14, 8061-8069.	3.2	84
39	Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas. Cancer, 2007, 109, 1863-1869.	2.0	81
40	Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).. Journal of Clinical Oncology, 2016, 34, 3544-3544.	0.8	79
41	Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology, 2005, 23, 9011-9011.	0.8	78
42	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. Journal of Clinical Oncology, 2020, 38, 2140-2150.	0.8	68
43	Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 785-785.	0.8	67
44	An Update on Immunotherapy for Solid Tumors: A Review. Annals of Surgical Oncology, 2018, 25, 3404-3412.	0.7	66
45	Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).. Journal of Clinical Oncology, 2018, 36, 4123-4123.	0.8	64
46	Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. British Journal of Cancer, 2002, 86, 12-13.	2.9	59
47	A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. PLoS ONE, 2015, 10, e0144559.	1.1	58
48	Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clinical Cancer Research, 2015, 21, 3216-3229.	3.2	58
49	Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. International Journal of Cancer, 2016, 138, 671-678.	2.3	56
50	MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors. Cancer Discovery, 2018, 8, 988-1005.	7.7	55
51	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. Journal of Clinical Oncology, 2016, 34, 2258-2264.	0.8	52
52	Nivolumab for the treatment of colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 611-618.	1.1	52
53	A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 9051-9051.	0.8	52
54	Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation. Clinical Cancer Research, 2011, 17, 5152-5160.	3.2	49

#	Article	IF	Citations
55	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. Journal of Clinical Oncology, 2017, 35, 519-519.	0.8	49
56	Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta OncolÃ³gica, 2015, 54, 487-492.	0.8	46
57	Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Lung Cancer, 2020, 146, 310-317.	0.9	46
58	Antiangiogenic Therapies Targeting the Vascular Endothelia Growth Factor Signaling System. Critical Reviews in Oncogenesis, 2012, 17, 51-67.	0.2	46
59	A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Targeted Oncology, 2015, 10, 99-109.	1.7	45
60	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, e9-e15.	1.0	45
61	SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology, 2004, 22, 3001-3001.	0.8	45
62	A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. British Journal of Cancer, 2014, 111, 2254-2261.	2.9	44
63	Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival. Clinical Colorectal Cancer, 2015, 14, 185-191.	1.0	42
64	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Scientific Reports, 2019, 9, 14551.	1.6	41
65	Patient Age and Comorbidity Are Major Determinants of Adjuvant Chemotherapy Use for Stage III Colon Cancer in Routine Clinical Practice. Journal of Clinical Oncology, 2008, 26, 4516-4517.	0.8	38
66	SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology, 2004, 22, 3001-3001.	0.8	38
67	Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. Journal of Clinical Investigation, 2019, 129, 1940-1945.	3.9	37
68	BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).. Journal of Clinical Oncology, 2019, 37, 358-358.	0.8	37
69	Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. British Journal of Cancer, 2015, 113, 979-988.	2.9	35
70	Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Targeted Oncology, 2015, 10, 179-188.	1.7	35
71	A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. Investigational New Drugs, 2018, 36, 1026-1036.	1.2	35
72	A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 560-560.	0.8	35

#	Article	IF	Citations
73	Developing a national database for metastatic colorectal cancer management: perspectives and challenges. Internal Medicine Journal, 2013, 43, 1224-1231.	0.5	33
74	OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC. Journal of Thoracic Oncology, 2019, 14, S208.	0.5	32
75	Genderâ€specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. International Journal of Cancer, 2009, 125, 426-431.	2.3	31
76	Systematic Review of Clinical Outcomes Following Various Treatment Options for Patients with Extraabdominal Desmoid Tumors. Annals of Surgical Oncology, 2018, 25, 1544-1554.	0.7	31
77	ASO Author Reflections: Immunotherapy for Solid Tumors: A Review. Annals of Surgical Oncology, 2018, 25, 974-975.	0.7	29
78	Longâ€term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer, 2021, 127, 884-893.	2.0	29
79	Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab Â± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).. Journal of Clinical Oncology, 2021, 39, 9047-9047.	0.8	28
80	Impact of diabetes on clinicopathologic and genetic features of colorectal cancer formation.. Journal of Clinical Oncology, 2013, 31, 426-426.	0.8	28
81	A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Investigational New Drugs, 2018, 36, 1060-1071.	1.2	27
82	Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repairâ€“Proficient Stage II Colon Cancer. Clinical Cancer Research, 2016, 22, 3488-3498.	3.2	26
83	The Past, Present, and Future of Cytotoxic Chemotherapy and Pathway-Directed Targeted Agents for Soft Tissue Sarcoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e386-e393.	1.8	25
84	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology, 2020, 38, 8-8.	0.8	25
85	Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. European Journal of Cancer, 2006, 42, 864-870.	1.3	24
86	Nutlin-3a Efficacy in Sarcoma Predicted by Transcriptomic and Epigenetic Profiling. Cancer Research, 2014, 74, 921-931.	0.4	24
87	A Malignant Neoplasm From the Jejunum With aMALAT1-GLI1Fusion and 26-Year Survival History. International Journal of Surgical Pathology, 2020, 28, 553-562.	0.4	24
88	Therapeutic strategies to remodel immunologically cold tumors. Clinical and Translational Immunology, 2020, 9, e1226.	1.7	23
89	Survival impact of the Australian National Bowel Cancer Screening Programme. Internal Medicine Journal, 2016, 46, 166-171.	0.5	22
90	Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors. Current Treatment Options in Oncology, 2002, 3, 489-496.	1.3	21

#	Article	IF	Citations
91	Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies. Clinical Cancer Research, 2018, 24, 3465-3474.	3.2	21
92	A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2018, 36, 2515-2515.	0.8	20
93	Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Critical Reviews in Oncology/Hematology, 2013, 85, 121-135.	2.0	19
94	A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. Investigational New Drugs, 2018, 36, 886-894.	1.2	18
95	A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study.. Journal of Clinical Oncology, 2017, 35, 3557-3557.	0.8	17
96	BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).. Journal of Clinical Oncology, 2018, 36, 4512-4512.	0.8	17
97	Outcomes of Patients With Maxillofacial Osteosarcoma: A Review of 15 Cases. Journal of Oral and Maxillofacial Surgery, 2012, 70, 734-739.	0.5	16
98	Examining the impact of regular aspirin use and <scp>PIK3CA</scp> mutations on survival in stage 2 colon cancer. Internal Medicine Journal, 2017, 47, 88-98.	0.5	16
99	Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression. Pathology, 2019, 51, 655-657.	0.3	16
100	New biomarkers for checkpoint inhibitor therapy. ESMO Open, 2020, 5, e000597.	2.0	16
101	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. Journal of Clinical Oncology, 2018, 36, 11502-11502.	0.8	16
102	Recombinant human erythropoietin in cancer-related anemia: an evidence-based review. Best Practice and Research in Clinical Haematology, 2005, 18, 389-406.	0.7	15
103	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 2016, 16, 339.	1.1	15
104	Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). Journal of Clinical Oncology, 2004, 22, 9024-9024.	0.8	15
105	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open, 2021, 6, 100328.	2.0	15
106	Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management*. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 167-176.	0.7	14
107	Response assessment in gastrointestinal stromal tumor. International Journal of Cancer, 2011, 128, 1251-1258.	2.3	14
108	Wiki-Based Clinical Practice Guidelines for the Management of Adult Onset Sarcoma: A New Paradigm in Sarcoma Evidence. Sarcoma, 2015, 2015, 1-6.	0.7	14

#	Article	IF	Citations
109	Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services. Clinical Sarcoma Research, 2016, 6, 11.	2.3	14
110	Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). Journal of Clinical Oncology, 2004, 22, 9024-9024.	0.8	14
111	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 688-688.	0.8	14
112	Soft-tissue Sarcomas in the Asia-Pacific Region: A Systematic Review. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6821-6832.	0.5	14
113	Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. Journal of Cancer Epidemiology, 2015, 2015, 1-8.	0.5	13
114	First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427). Contemporary Clinical Trials Communications, 2019, 16, 100409.	0.5	13
115	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Monthly Notices of the Royal Astronomical Society: Letters, 2021, 92, 493-499.	1.2	13
116	Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study.. Journal of Clinical Oncology, 2022, 40, 162-162.	0.8	13
117	Histone deacetylase inhibitors in cancer: What have we learned?. Cancer, 2015, 121, 1164-1167.	2.0	12
118	Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases. Current Oncology, 2021, 28, 3659-3667.	0.9	12
119	A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2524-2524.	0.8	12
120	MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)â€“based combinations in gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2019, 37, TPS467-TPS467.	0.8	12
121	Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer. OncoImmunology, 2016, 5, e1149667.	2.1	11
122	Clinical Use of Therapies Targeting Tumor Vasculature and Stroma. Current Cancer Drug Targets, 2008, 8, 498-508.	0.8	10
123	Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody. Medical Oncology, 2011, 28, 162-164.	1.2	10
124	An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer. Annals of Oncology, 2012, 23, 2633-2637.	0.6	10
125	Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centre. ANZ Journal of Surgery, 2018, 88, 1151-1157.	0.3	10
126	Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood. Cancer Chemotherapy and Pharmacology, 2018, 82, 887-898.	1.1	10

#	Article	IF	Citations
127	Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer, 2011, 11, 313.	1.1	9
128	Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma. Clinical Colorectal Cancer, 2017, 16, e45-e54.	1.0	9
129	BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + antiâ€“epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. Annals of Oncology, 2018, 29, v109.	0.6	9
130	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. Clinical Colorectal Cancer, 2018, 17, 313-319.	1.0	9
131	Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open, 2022, 7, 100477.	2.0	9
132	Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy. Analytical Biochemistry, 2010, 406, 41-50.	1.1	8
133	CD8⁺ tumorâ€infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival. Clinical and Translational Immunology, 2020, 9, e1155.	1.7	8
134	Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. Journal of Clinical Oncology, 2004, 22, 3010-3010.	0.8	8
135	Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 43-52.	0.7	7
136	Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. JCO Precision Oncology, 2021, 5, 1160-1165.	1.5	7
137	Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective. Cost Effectiveness and Resource Allocation, 2020, 18, 5.	0.6	7
138	Patient Comorbidities and Behaviour Once Diagnosed Are Major Contributors to Disparities in Cancer Health Outcomes. Journal of Clinical Oncology, 2010, 28, e36-e37.	0.8	6
139	Controversies in the management of gastrointestinal stromal tumors. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 216-227.	0.7	6
140	Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 361-367.	0.7	6
141	<scp>KRAS</scp> mutation testing of metastatic colorectal cancer in <scp>A</scp>ustralia: Where are we at?. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 261-265.	0.7	6
142	Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in <scp>A</scp>ustralia. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 262-271.	0.7	6
143	Exploring the feasibility and utility of exomeâ€scale tumour sequencing in a clinical setting. Internal Medicine Journal, 2018, 48, 786-794.	0.5	6
144	Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. Journal of Clinical Oncology, 2004, 22, 3010-3010.	0.8	6

#	Article	IF	Citations
145	First-in-man trial of 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO) as a continuous intravenous infusion (CIVI), in patients (pt) with advanced solid tumours.. Journal of Clinical Oncology, 2016, 34, e14025-e14025.	0.8	6
146	Intra-patient dose escalation in Ewingâ€™s sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review. Clinical Sarcoma Research, 2013, 3, 15.	2.3	5
147	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology. Npj Precision Oncology, 2021, 5, 58.	2.3	5
148	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.. Journal of Clinical Oncology, 2016, 34, 3511-3511.	0.8	5
149	Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.. Journal of Clinical Oncology, 2017, 35, 3548-3548.	0.8	5
150	Impact of Body Mass Index on Colorectal Cancer Treatment and Outcomes: Need for Prospective and Comprehensive Data. Journal of Clinical Oncology, 2009, 27, 1524-1526.	0.8	4
151	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. JNCI Cancer Spectrum, 2019, 3, pkz071.	1.4	4
152	Novel Vaccine Targeting Colonic Adenoma: a Pre-clinical Model. Journal of Gastrointestinal Surgery, 2019, 23, 626-633.	0.9	4
153	Recurrent SPECC1Lâ€“NTRK fusions in pediatric sarcoma and brain tumors. Journal of Physical Education and Sports Management, 2020, 6, a005710.	0.5	4
154	Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248. Journal of Clinical Oncology, 2005, 23, 3006-3006.	0.8	4
155	Mesenchymal chondrosarcoma: An Australian multiâ€centre cohort study. Cancer Medicine, 2023, 12, 368-378.	1.3	4
156	Consensus approaches to best practice management of gastrointestinal stromal tumors. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 188-198.	0.7	3
157	Microsatellite Instability Status Is Critical to Analysis of Survival in Stage II Colon Cancer. Journal of Clinical Oncology, 2012, 30, 675-676.	0.8	3
158	A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 3066-3066.	0.8	3
159	Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, TPS3113-TPS3113.	0.8	3
160	Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer. Journal of the National Cancer Institute, 2008, 100, 1739-1739.	3.0	2
161	Optimising the management of soft tissue tumours. Pathology, 2011, 43, 295-301.	0.3	2
162	An Australasian perspective on sarcoma research, translational biology and clinical trials: the Australasian Sarcoma Study Group (ASSG). Pathology, 2014, 46, 160-163.	0.3	2

#	Article	IF	Citations
163	Personalized Management: Inoperable Gastrointestinal Stromal Tumors. Clinical Gastroenterology and Hepatology, 2014, 12, 130-134.	2.4	2
164	Variations of Surveillance Practice for Patients with Bone Sarcoma: A Survey of Australian Sarcoma Clinicians. Sarcoma, 2017, 2017, 1-9.	0.7	2
165	Precision oncology using a clinicianâ€directed, tailored approach to molecular profiling. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 84-90.	0.7	2
166	BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. Targeted Oncology, 2021, 16, 227-236.	1.7	2
167	On-treatment progression-free survival analysis of aflibercept-FOLFIRI treatment within 28 days of progression in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.. Journal of Clinical Oncology, 2013, 31, 469-469.	0.8	2
168	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. Targeted Oncology, 2022, 17, 95.	1.7	2
169	Abstract CT503: A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies. Cancer Research, 2022, 82, CT503-CT503.	0.4	2
170	First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Targeted Oncology, 2016, 11, 149-156.	1.7	1
171	Wither surgical oncology?. ANZ Journal of Surgery, 2019, 89, 10-11.	0.3	1
172	Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. Internal Medicine Journal, 2020, 50, 165-172.	0.5	1
173	Using Genomic Sequencing to Explain an Exceptional Response to Therapy in a Malignant Phyllodes Tumor. JCO Precision Oncology, 2020, 4, 1263-1266.	1.5	1
174	85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study). Annals of Oncology, 2020, 31, S1276.	0.6	1
175	CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research. JCO Clinical Cancer Informatics, 2020, 4, 136-146.	1.0	1
176	Prescribing patterns for bevacizumab in first-line metastatic colorectal cancer: Exploring the introduction of a new drug into routine clinical practice.. Journal of Clinical Oncology, 2012, 30, 665-665.	0.8	1
177	Patterns of care according to treatment intent for metastatic colorectal cancer (mCRC): A two-year review of routine practice.. Journal of Clinical Oncology, 2012, 30, 682-682.	0.8	1
178	Massively parallel sequencing (MPS) of circulating DNA in patients with metastatic colorectal cancer (mCRC): Prognostic significance and early changes during chemotherapy (CT).. Journal of Clinical Oncology, 2013, 31, 11015-11015.	0.8	1
179	Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)?. Journal of Clinical Oncology, 2013, 31, 410-410.	0.8	1
180	Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, e14558-e14558.	0.8	1

#	Article	IF	Citations
181	Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.. Journal of Clinical Oncology, 2017, 35, 3572-3572.	0.8	1
182	Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.. Journal of Clinical Oncology, 2019, 37, e18236-e18236.	0.8	1
183	Metastatic colorectal cancer and management in public versus private hospitals: Similarities and differences.. Journal of Clinical Oncology, 2013, 31, 497-497.	0.8	1
184	Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, 386-386.	0.8	1
185	Delivery and effectiveness of adjuvant therapy for stage III colon cancer in routine clinical practice.. Journal of Clinical Oncology, 2014, 32, e14540-e14540.	0.8	1
186	ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours.. Neuro-Oncology, 2022, 24, i6-i7.	0.6	1
187	Response to â€œDisparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Settingâ€• Oncologist, 2009, 14, 104-105.	1.9	0
188	What is the future potential of the PI3K pathway in colorectal cancer treatment?. Colorectal Cancer, 2014, 3, 113-116.	0.8	0
189	Maxillofacial osteosarcoma: outcomes and update of current treatment protocols. International Journal of Oral and Maxillofacial Surgery, 2015, 44, e53.	0.7	0
190	ATRT-27. A PHASE II STUDY OF PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH SOLID TUMORS INCLUDING MALIGNANT RHABDOID TUMOR/ATYPICAL TERATOID RHABDOID TUMOURS. Neuro-Oncology, 2018, 20, i33-i33.	0.6	0
191	A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2021, 87, 613-620.	1.1	0
192	Patterns of care according to treatment intent for metastatic colorectal cancer (mCRC): A 2.5-year review of routine practice.. Journal of Clinical Oncology, 2012, 30, e16516-e16516.	0.8	0
193	Clinicopathologic and molecular associations of PIK3CA and PTEN mutation in colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 3623-3623.	0.8	0
194	Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, TPS2619-TPS2619.	0.8	0
195	Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, 3598-3598.	0.8	0
196	Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy.. Journal of Clinical Oncology, 2013, 31, e14608-e14608.	0.8	0
197	On-treatment progression-free survival analysis of ziv-aflibercept/FOLFIRI treatment within 28 days of end of treatment in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.. Journal of Clinical Oncology, 2013, 31, 3573-3573.	0.8	0
198	Are the survival benefits associated with primary resection in de novo metastatic colorectal cancer (mCRC) mediated by reversal of systemic inflammation?. Journal of Clinical Oncology, 2014, 32, 464-464.	0.8	0

#	Article	IF	Citations
199	Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response) Tj ETQq1 1 0.784314 rgBT /Overlock of Clinical Oncology, 2014, 32, e14536-e14536.	0.8	0
200	Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care.. Journal of Clinical Oncology, 2014, 32, e17637-e17637.	0.8	0
201	Prognostic impact of clinicopathologic features in metastatic rectal versus colon cancer.. Journal of Clinical Oncology, 2014, 32, e14518-e14518.	0.8	0
202	Survival impact of adjuvant chemotherapy for resected early-stage rectal adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, 712-712.	0.8	0
203	Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 685-685.	0.8	0
204	Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 738-738.	0.8	0
205	The value of networks in driving phase I trials: the Peter MacCallum Cancer Centre experience. Chinese Clinical Oncology, 2019, 8, 23-23.	0.4	0
206	The Role of Systemic Therapies in the Management of Soft Tissue Sarcoma. , 2021, , 169-188.		0
207	Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 605-613.	0.7	0